Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

NCT04272151 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Multiple Myeloma in Relapse
Neoplasm, Plasma Cell

Interventions

BIOLOGICAL: BCMA CAR-T cells

Sponsor

Chongqing Precision Biotech Co., Ltd